Withdrawals due to adverse events · patients with tension‐type headache
SSRIs or SNRIs showed no clear difference in withdrawals due to adverse events compared with other antidepressants (low certainty).
1 finding from 1 review
Headache intensity (mean score) · patients with tension‐type headache
1 finding from 1 review
Headache duration (hours) · patients with tension‐type headache
1 finding from 1 review
Symptomatic/analgesic medication use for acute headache attacks · patients with tension‐type headache
1 finding from 1 review
Headache index · patients with tension‐type headache
1 finding from 1 review
Quality of life · patients with tension‐type headache
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with tension‐type headache
It is very uncertain whether SSRIs or SNRIs changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Headache (frequency) · patients with tension‐type headache
1 finding from 1 review
Headache intensity (mean score) · patients with tension‐type headache
1 finding from 1 review
Intervention not reported
At least 50% reduction in pain or equivalent (substantial) · adults with fibromyalgia
It is very uncertain whether the intervention changes at least 50% reduction in pain or equivalent (substantial) (very low certainty).
1 finding from 1 review
Intervention not reported
At least 30% reduction in pain or equivalent (moderate) · adults with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse event withdrawals · adults with fibromyalgia
It is very uncertain whether the intervention changes adverse event withdrawals (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Death · adults with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993 (5 mg tds): sweating 37%, headache 15%, urinary frequency 14%, vasodilatation 12%, dizziness 10%, dyspepsia 10%, nausea 8%, asthenia 8%, diarrhoea 5%; 6% withdrew at 5 mg tds and 29% at 10 mg tds. LeVeque…
2 studies · 278 participants
GRADE not reported
Other oral symptoms (dysgeusia, dysphagia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Dry mouth (xerostomia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Davies 1994 (cross-over, 20 participants): mean improvement in VAS score 22.5 mm with pilocarpine vs 15.2 mm with artificial saliva (100 mm scale). The improvement was greater with pilocarpine but was not statistically…
1 study · 20 participants
GRADE not reported
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Davies 1994: main side effects with pilocarpine were nausea 20%, sweating 15%, lacrimation 10%. One participant definitely withdrew because of side effects; another may have.
1 study · 20 participants
GRADE not reported
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
The intervention leads to higher at least 50% of maximum pain relief over 4 to 6 hours (high certainty).
1 finding from 1 review
RR 5.6 [4, 7.8]
Studies not reported
High
Intervention not reported
Participants with at least 1 adverse event · adults with moderate or severe acute postoperative pain
The intervention showed no clear difference in participants with at least 1 adverse event (moderate certainty).
1 finding from 1 review
RR 0.93 [0.74, 1.2]
Studies not reported
Moderate